www.thelancet.com/neurology Vol 11 October 2012 891
Lancet Neurol 2012; 11: 891–905
Neuromuscular Research Unit,
Tampere University and
University Hospital, Tampere,
Finland (B Udd MD); and
Department of Genetics,
University of Texas MD
Anderson Cancer Center,
Houston, TX, USA (R Krahe PhD)
Dr Bjarne Udd, Neuromuscular
Research Unit, Tampere
University and University
Hospital, 33520 Tampere,
Dr Ralf Krahe, Department of
Genetics, University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA
The myotonic dystrophies: molecular, clinical, and
Bjarne Udd, Ralf Krahe
Myotonic dystrophy is the most common type of muscular dystrophy in adults and is characterised by progressive
myopathy, myotonia, and multiorgan involvement. Two genetically distinct entities have been identifi ed. Myotonic
dystrophy type 1 (also known as Steinert’s disease) was fi rst described more than 100 years ago, whereas myotonic
dystrophy type 2 was identifi ed only 18 years ago, after genetic testing for type 1 disease could be applied. Both
diseases are caused by autosomal dominant nucleotide repeat expansions. In patients with myotonic dystrophy type 1,
a (CTG)n expansion is present in DMPK, whereas in patients with type 2 disease, there is a (CCTG)n expansion in
CNBP. When transcribed into CUG-containing RNA, mutant transcripts aggregate as nuclear foci that sequester
RNA-binding proteins, resulting in a spliceopathy of downstream eff ector genes. The prevailing paradigm therefore
is that both disorders are toxic RNA diseases. However, research indicates several additional pathogenic eff ects take
place with respect to protein translation and turnover. Despite clinical and genetic similarities, myotonic dystrophy
type 1 and type 2 are distinct disorders requiring diff erent diagnostic and management strategies.
The myotonic dystrophies are the subject of extensive
research because of their clinical importance and intri-
guing molecular biology. Progressive muscle degen-
eration leading to disabling weakness and wasting with
myotonia, in combination with multisystem involve-
ment, are the main characteristics of myotonic
dystrophy type 1 (also known as Steinert’s disease)1 and
myotonic dystrophy type 2.2–4 Myotonic dystrophy type 1
was fi rst recognised clinically more than 100 years ago.
However, type 2 disease was recognised only 18 years
ago, after genetic testing for myotonic dystrophy type 1
could be applied in clinical practice. Originally referred
to as proximal myotonic myopathy2,3 or proximal
myotonic dystrophy,4 the current nomenclature of
type 1 and type 2 disease was adopted after genetic
mapping of the myotonic dystrophy type 2 locus to
Repeat expansions are the mutations underlying both
types of myotonic dystrophy: type 1 disease is caused by a
(CTG)n microsatellite repeat expansion in the untrans-
lated 3′ region of DMPK in chromosome 19q13.3,6–8
whereas type 2 disease is due to a (CCTG)n expansion in
intron 1 of CNBP in chromosome 3q21.3.9,10 Both
mutations lead to formation of transcript aggregates in
the nucleus, so-called foci, which interfere with proteins
that play a part in RNA metabolism, including members
of the muscleblind (MBNL) family of RNA-binding
proteins.11 Both diseases are characterised by missplicing
of several downstream eff ector genes, which are thought
to account, at least in part, for multiorgan involvement.12
Despite clinical and genetic similarities, myotonic
dystrophy types 1 and 2 are clearly diff erent disorders
with distinct characteristics, requiring their own
diagnostic and management strategies.13
Identifi cation of toxic CUG RNA repeats in type 1
disease or CCUG repeats in type 2 disease was the
fi rst major pathomechanism found to underlie these
spliceopathies. The past 5 years of research have
provided new insights and contributed to our
understanding of the molecular complexity of these
diseases. Increased understanding of the psychosocial
eff ects of myotonic dystrophy type 1 and the overall
burden of the disease has enlarged the clinical scope and
refi ned therapeutic outcome measures. Despite raised
awareness of the disease, myotonic dystrophy type 2
remains largely underdiagnosed. Our Review covers the
current state of the fi eld, introduces new aspects of
disease charac ter istics, and outlines developments in
therapeutic eff orts.
Before identifi cation of the distinct genetic mutations,
the combined prevalence of the myotonic dystrophies
was estimated at 1 in 8000 (12·5/100 000), based on
clinical ascertainment.1 However, prevalence estimates
vary widely for diff erent populations. High prevalence
has been reported in northern Sweden, the Quebec
region in Canada, and the Basque region of Spain.1
Findings of a population genetics study in Finland14
showed that the frequency of the myotonic dystrophy
type 2 mutation (1/1830) can be much higher than that
for type 1 mutations (1/2760) in the same population.14
However, it is unknown whether mutation frequencies
in the Finnish population refl ect those for popu lations
elsewhere of European descent and if the mutation is
100% penetrant in all circumstances. Considering the
generally earlier onset of symptoms in myotonic
dystrophy type 1, these data suggest a prevalence in
Finland of about 20 in 100 000 for both myotonic
dystrophy type 1 and type 2 disease.14 Many patients in
older generations with myotonic dystrophy type 1 or
type 2 with milder symptoms are clearly undiagnosed.
It is noteworthy that recessive mutations in the
chloride channel gene CLCN1, which have a high
frequency in the general population, can act as
modifi ers in patients with type 2 disease by
amplifi cation of their myotonia.15
www.thelancet.com/neurology Vol 11 October 2012
Patients with myotonic dystrophy type 1 can present
with four diff erent forms on initial examination: adult-
onset, congenital, childhood-onset, and late-onset
oligosymptomatic.1,16 Adult-onset disease is the most
prevalent form. In myotonic dystrophy type 2, there are
no distinct clinical subgroups; congenital and
childhood-onset forms have not been described, and
clinical presentation comprises a continuum ranging
from early adult-onset severe forms to very late-onset
mild forms that are diffi cult to diff erentiate from
normal ageing. The diff erent clinical manifestations in
the two diseases are summarised in table 1.
Adult-onset myotonic dystrophy type 1
Diagnostic eff orts are usually initiated because of muscle
weakness, myotonia, or cataracts, the three cardinal
symptoms of myotonic dystrophy type 1. A family history
of type 1 disease combined with minor symptoms is a
common starting point for diagnostic examinations.
However, if the main symptom is muscle weakness,
referral for assessment frequently happens at a late
disease stage, when symptoms and fi ndings could be
quite advanced. Myotonia is either reported as stiff ness
by the patient or their parents from school age to the
third decade of life or identifi ed at a later time during
clinical or electro physiological examinations. However,
in early adulthood, muscle weakness can be totally
absent. Cataracts lead to ophthalmological examinations
and surgical removal but do not usually initiate further
diagnostic considerations for myotonic dystrophy type 1,
at least when diagnosed at an older age.
Skeletal muscle weakness, leading to immobility,
respiratory insuffi ciency, dysarthria, and dysphagia, is the
major cause of severe disability and death at late stages of
adult-onset myotonic dystrophy type 1.18 Muscle weakness
develops in facial, neck, and distal limb muscles in
parallel with muscle wasting. Atrophy in the temporal
muscles together with ptosis contributes to a characteristic
myopathic facial appearance, which is underscored by
frontal balding in men. Myotonia is invariably present in
adult-onset myotonic dystrophy type 1 on both clinical
examination and electromyog raphy,1 but can occasionally
be relatively subtle clinically. The most common sign is
percussion myotonia in the thenar muscle and, less
consistently, grip myotonia on activation. Myotonia can
be relieved by repeat activation (warm-up).19
Cardiac conduction defects and tachyarrhythmias
might lead to early heart spells and cardiac death.20 The
underlying pathological fi nding is fi brosis in the
conduction system and sinoatrial node.20 Clinically
manifest dilated or hypertrophic cardiomyopathy leading
to heart failure is not consistently part of the disease
spectrum of adult-onset myotonic dystrophy type 1, even
if subclinical changes can be recorded.
Cataracts are iridescent posterior subcapsular opacities
and are almost pathognomonic for adult-onset myotonic
dystrophy type 1.21 Too often the exact type of cataract is
not defi ned before surgical removal. Occurrence of
cataracts before age 50 years should alert the clinician
to consider myotonic dystrophy. Retinal degenerative
changes have been documented pathologically.1,22
Brain abnormalities in adult-onset myotonic dystrophy
type 1 are both structural and functional. The most
characteristic neuropsychiatric feature is a personality
mode consisting of avoidance and reduced perception of
disease symptoms and signs, mild cognitive impairment,
and later apathy. Daytime sleepiness is invariably present
at the stage of physical disability and is only infrequently
due to obstructive apnoea.23,24 Together, these changes
might lead to low education levels, reduced professional
activity, and socioeconomic disadvantage.25 On brain
MRI scans, diff use white-matter changes are more
evident than atrophy.26
Gastrointestinal symptoms are frequent complaints in
patients with adult-onset myotonic dystrophy type 1,
ranging from constipation to diarrhoea and incon-
tinence.27 Occurrence of gallbladder disorders is in-
creased,1,22 and dysphagia can become a major concern at
the disability stage, with aspirations and pneumonia.1,22
Endocrine functions are impaired in several ways in
adults with myotonic dystrophy type 1. Insulin resistance
and susceptibility for diabetes are well documented.1
Hypothyroidism has been shown to worsen and mask
symptoms of myotonic dystrophy.1 Male hypogonadism
is a regular feature, and male infertility and miscarriages
are common in these patients.1
In adult-onset type 1 disease, skin can be aff ected. Early
frontal balding is more typical in men than women.
Pilomatricomas and epitheliomas are not uncommon,
but are frequently unrecognised or misdiagnosed.1
Congenital myotonic dystrophy type 1
The most severe form of congenital myotonic dystrophy
type 1 presents prenatally by reduced fetal movements,
polyhydramnios, and various deformities detected on
ultrasound examination.1,22 At birth, babies have severe
hypotonia in limb, trunk, respiratory, facial, and bulbar
muscles, leading to respiratory failure and feeding
diffi culties.1,22 This extreme muscle weakness is not
caused by degenerative changes but by develop mental
defects. Mental retardation is also seen. With intensive
care, infants survive and no longer need assisted ven-
tilation. Even if delayed, they can achieve developmental
milestones and independent walking.1,22 In advanced
disease, myotonia can be manifest and so can degen er-
ative muscle processes in the second decade.
Childhood-onset myotonic dystrophy type 1
This form of type 1 disease has long been neglected
because of symptoms uncharacteristic for a muscular
dystrophy. Children do not present with muscle weak-
ness, wasting, or myotonia. Instead, they have diffi culties
at school that generally initiate a search by paediatric
www.thelancet.com/neurology Vol 11 October 2012 893
neurologists for causes of mental retardation.28,29 In many
cases, the true nature of the brain disorder is not
understood until a parent, usually the mother, is diagnosed
with adult-onset myotonic dystrophy type 1. As with
congenital type 1 disease, children with childhood-onset
myotonic dystrophy type 1 will develop muscle symptoms
at an older age, causing physical disabilities comparable
with severe adult-onset type 1 disease.28,29
Adult-onset myotonic dystrophy
Myotonic dystrophy type 2
Intron 1Location of the expansion
3′ untranslated region
Myotonia on electromyography
Muscle w eakness
Localisation of muscle weakness
Face or jaw
Distal limb muscle
Proximal limb muscle
Muscle strength variations
Visible muscle atrophy
Laboratory fi ndings
Concentration of creatine kinase in serum
Muscle biopsy fi ndings
Nuclear clump fi bres
Ring fi bres
Other neurological symptoms
Frontal balding in men
Incapacity (work and activities of daily living)
Typical in adult onset
Disability often by age 30–50 years
Present in less than 50%
Absent and variable in many patients; needs detailed investigation
Disability at age 60–85 years
Present in a few patients at diagnosis
Generally present later in life
Generally present later in life
Can be absent for many years
Rare, mild, or moderate
Exceptionally rare cases
Flexor digitorum profundus in some patients
Main disability in most patients, late onset
Prominent in few patients
Absent or moderate
Face, temporal, distal hands, and legs
Most disabling symptom in many patients
Can be considerable
Present in at least 50%
Normal-to-moderate increaseNormal-to-moderate increase
Smallness of type 1 fi bres
In late stage only
Very frequent in distal muscles
Massive in distal muscle
Highly atrophic type 2 fi bres
Scattered early before weakness
Variable and mainly in type 2 fi bres
Common Highly variable, absent to severe
Prominent in many patients
Typically after age 30–35 years
Rarely younger than 60 years, unless severe pain
Modifi ed from Vihola and colleagues,17 with permission of Springer-Verlag.
Table 1: Clinical manifestations in the myotonic dystrophies
www.thelancet.com/neurology Vol 11 October 2012
Late-onset oligosymptomatic myotonic dystrophy type 1
In many families with adult-onset type 1 disease, the
ancestor who transmitted the mutation in earlier
generations might have had very mild symptoms, such
as cataracts treated surgically or late moderate muscle
atrophy.1 This mild expression in previous generations
combined with severe disease in later generations
(usually the third) was the basis for the characterisation
of genetic anticipation in myotonic dystrophy type 1 long
before genetic testing could be applied.1 The milder
disorder has been correlated loosely with shorter mutant
Myotonic dystrophy type 2
Patients with myotonic dystrophy type 2 may present in
many diff erent ways. The clinical phenotype is highly
variable, ranging from disabilities at age 40 years onwards
or early cardiac death, to mild proximal weakness that is
hardly recognisable, to slightly raised concentrations of
creatine kinase in elderly patients. The fi rst subjective
muscle symptom is usually either proximal lower limb
weakness, causing diffi culties with climbing stairs, or
myalgic pains. Cardinal features of myotonic dystrophy
type 1, such as myotonia, can be absent in patients with
type 2 disease, even on electromyography, and cataracts
are present in few individuals at the time of diagnosis
(table 1). Generally, by contrast with adult-onset myotonic
dystrophy type 1, muscle weakness in type 2 disease
begins at a later stage, the clinical course is more
favourable, and life expectancy is almost normal.13,30 The
severe congenital or childhood-onset forms that arise in
type 1 disease have not been noted in families aff ected by
myotonic dystrophy type 2.13 Abnormalities in social
skills and cognitive abilities are typically mild or absent.
Furthermore, no prominent late weakness of the
respiratory, facial, and bulbar muscles is seen (table 1).13
In myotonic dystrophy type 2, manual skills remain
largely intact, and patients are spared from complications
of general anaesthesia. However, severe variants of type 2
disease can occur, including fatal arrhythmic cardiac
complications, severe respiratory failure, progressive
muscular atrophy, and disability.4,13 In a comparison of
patients with type 1 or 2 myotonic dystrophy, the
frequency of severe cardiac conduction disturbances was
lower in patients with type 2 disease than in patients with
By contrast to these overall milder symptoms, patients
with myotonic dystrophy type 2 can have severe myalgic
pain as the major cause of dysfunction, aff ecting
professional performance (table 1).31–33 The pain is not
distinguishable from fi bromyalgia and does not respond
well to conventional pain treatment, although about 24%
of patients use continuous pain medication.13,32,33 By
contrast with type 1 disease, patients with myotonic
dystrophy type 2 frequently show hypertrophy of calf
muscles.13 Studies of gastrointestinal symptoms, dys-
phagia, and sleep suggest that these manifestations are
frequently not addressed in type 2 disease. Daytime
sleepiness does not occur, despite reported fatigue, but
sleep disturbances of other types are common and
frequently caused by myalgic pains, leading to increased
In patients with myotonic dystrophy type 1, (CTG)n
expansions range from 51 repeats to several thousands,
whereas healthy individuals carry 5–37 repeats.22 Repeat
lengths of 38–50 are considered premutation alleles,
whereas 51–100 repeats are protomutations, both of
which show increased instability towards expansion.
Carriers of premutations or protomutations present no
or few mild symptoms, such as cataracts. Patients with
adult-onset myotonic dystrophy type 1 carry more than
100 repeats, and those with congenital type 1 disease have
more than 1000 repeats.
In myotonic dystrophy type 1, repeat expansion length
is predictive of clinical severity and age of onset.
Progenitor allele length is the major modifi er of age of
onset and is altered itself by the level of instability in
somatic tissues (termed somatic instability), which
seems to be highly heritable and could be related to
individual-specifi c trans-acting modifi ers that might
contribute to the development of cancer and ageing.34
Although signifi cant correlations have been reported
between genotype and some phenotypic aspects (eg, age
of onset),16,35,36 other geno type-phenotype correlations are
unclear, possibly due to imprecision in phenotypic data
and diff ering levels of instability of mutant alleles in
various somatic tissues.22,34,37–40 Variant repeats within the
repeat tract—eg, (CCG)n and (GGC)n repeats, part of the
overall (CTG)n repeat array—can greatly alter both
mutational dynamics and phenotypic manifestations.41
Such variation is pres ent in up to 4% of unrelated
individuals with myotonic dystrophy type 141 but might
have gone undetected in patients presenting with atypical
manifestations. Tissue-specifi c changes of the myotonic
dystrophy type 1 repeat with complex non-CTG repeat
insertions might also aff ect phenotypic manifestations.42
The tendency of the repeat tract to expand or contract
seems to be a function of its primary sequence, which
enables formation of secondary hairpin structures, and
its genomic location, including fl anking sequences and
the distance from the origin of replication.43 Data from
population-based mathematical modelling of mutant
myotonic dystrophy type 1 repeat alleles in DNA extracted
from peripheral blood leucocytes suggest that the bias
towards expansion is the cumulative eff ect of many
expansion and contraction events (possibly as frequently
as every other day) that seem to be coupled to DNA repair
or transcription rather than be dependent on DNA
Germ-cell instability is possibly the major determining
factor underlying the pronounced anticipation in
myotonic dystrophy type 1.22 The expansion seems to
www.thelancet.com/neurology Vol 11 October 2012 895
increase through successive generations, and there is a
modest inverse correlation between repeat size and age
of onset.22 However, in as many as 6% of parent-child
pairs, repeat contraction has been noted with paternal
transmissions (rarely even to the normal range), whereas
there is a tendency towards expansion in maternal
transmission.44,45 Paternal alleles seem more unstable,
but children with congenital myotonic dystrophy type 1
are born almost exclusively to aff ected mothers,
indicative of sex-specifi c diff erences in germline repeat
By contrast to the (CTG)n repeat in myotonic dystrophy
type 1, the (CCTG)n expansion in type 2 disease is part of
a complex repeat, with many, usually polymorphic, tracts
in the confi guration (TG)n(TCTG)n(CCTG)n(NCTG)n
(CCTG)n.9,10,47,48 Healthy alleles contain fewer than
30 copies of the (CCTG)n repeat. The 3′ (CCTG)n portion
of the overall tract, when not interrupted by cryptic
repeats (ie, the fi rst nucleotide of the CCTG unit can be
any other nucleotide), becomes unstable and shows
some of the highest mutation rates reported for
polymorphic microsatellites and unstable repeat expan-
sions.48 The smallest recorded alleles associated with a
clinical phenotype are (CCTG)55–75, some of which can be
mosaic for larger repeats (ie, have one predominant
allele and many additional mutant alleles of various
sizes), and expansions as large as 11 000 have been noted,
making diagnostic sizing a challenge.9,10,47–49 Although, in
general, type 2 expansions are clinically less severe, they
are, on average, signifi cantly larger than those seen in
type 1 disease.30,50 On the basis of scant data (since sizing
is rarely attempted nowadays), the average (CCTG)n
repeat length in myotonic dystrophy type 2 is about
5000.10,30 Because of the extreme somatic instability, the
threshold size of the disease-causing mutation remains
to be determined. Similar to type 1 disease, a premutation
and a protomutation range might exist. Uninterrupted
alleles of (CCTG)22–33 in European populations show
Continued somatic instability is common to both
myotonic dystrophy type 1 and type 2, and it gives rise to
intra-tissue, inter-tissue, and cell-type variability and
somatic mosaicism over a patient’s lifetime.9,10,37,38 Inter-
generational transmission of the two mutations, how-
ever, seems to be diff erent. While the myotonic dystrophy
type 1 mutation tends to increase in size over successive
generations, resulting in the characteristic pronounced
anticipation,22 the type 2 mutation shows both expansions
and contractions.10,30 This fi nding could explain the lack
of a congenital form of type 2 disease, the later onset of
symptoms, and the overall lack of anticipation in
myotonic dystrophy type 2. No apparent correlation is
seen between expansion size and age of onset or
phenotypic severity in type 2 disease.30 Diagnostic genetic
testing generally uses DNA from peripheral blood
leucocytes. However, somatic variation is considerable
both in type 1 and type 2 disease, and repeat sizes in
aff ected tissues such as muscle or brain are much larger
in myotonic dystrophy type 1.2,51
Myotonic dystrophy type 1 is most common in
populations of European descent, is present in Japan at
about half the frequency, and is rarer still in India.52–54 A
single kindred of myotonic dystrophy type 1 from sub-
Saharan Africa has also been identifi ed,55 but, in general,
type 1 disease is conspicuously absent in African
populations.53,56 Similarly, myotonic dystrophy type 2
seems to be mainly a disease of European populations:
most patients are of northern and eastern European
descent, but single kindreds of Afghan47,57 and Japanese58
origin have been identifi ed. Extensive linkage disequi lib-
rium of the type 1 and type 2 mutations suggests a single
or a few founder mutations.47,48,59 Both mutations occur
on a disease haplotype that, except for the expansions,
resembles most common normal haplotypes.47,48,59
Whether the extensive linkage disequilibrium is refl ective
of positive selection or the presence of a nearby cis
element predisposing to increased instability remains to
be determined.10,38,48 Both mutations are believed to have
occurred after migration out of Africa, between
120 000 and 60 000 years ago.50,53 The age of the myotonic
dystrophy type 2 founder mutation has been estimated at
4000–12 000 years (about 200–540 generations).10
The pathophysiological mechanisms that underlie the
myotonic dystrophies are considerably more complex
than previously anticipated.60–64 However, most of these
seem to converge on RNA toxicity (fi gure 1).
RNA toxicity and aberrant splicing
The transcription of mutant repeats into RNA appears
to be necessary and suffi cient to cause myotonic
dystrophy.65,66 Mutant CUG-containing RNA strands
interfere with trans-acting RNA-binding proteins leading
to increased amounts of CUGBP/Elav-like family
member 1 (CELF1) and reduced MBNL activity.62,67,68 In
the nucleus, the activity of MBNL proteins is diminished
because of their sequestration in ribonuclear foci.11,12,69,70
CELF1 steady-state concentrations are upregulated by
hyperphosphorylation via diff erent signalling kinases,
including protein kinase C (PKC),71 v-akt murine
thymoma viral oncogene homolog 1 (AKT1), cyclin D3
(CCND3), cyclin-dependent kinase 4 (CDK4),72 glycogen
synthase kinase 3 beta (GSK3B),73 and double-stranded
RNA-dependent protein kinase (PKR).74 All but PKR have
been linked mechanistically to the phosphorylation of
CELF1 in disease cells. In the nucleus, CELF1 and MBNL
proteins function as splice factors, and dysregulation of
both proteins (due to sequestration or inappropriate
phosphorylation) results in aberrant expression of
embryonic splice isoforms in adult tissues. To date, more
than 30 misspliced eff ector genes have been identifi ed as
targets of MBNL1, CELF1, or both. Mis splicing and loss
of function of these gene products is generally thought to
www.thelancet.com/neurology Vol 11 October 2012
account for the multisystemic phenotype in myotonic
dystrophy.67,75,76 For most mis spliced genes identifi ed so
far, patients with types 1 and 2 disease show comparable
splicing abnormalities, sug gesting that qualitative
diff erences in splicing do not account for phenotypic
diff erences. However, whereas missplicing of CLCN1 (by
giving rise to a non-functional transcript) can account for
myotonia,77–80 a clear pathogenic role for most other
misspliced genes has not been shown and evidence
Missplicing of exon 11 of the amphiphysin gene (BIN1),
mediated by MBNL1 loss, was linked to tubular defects in
both myotonic dystrophy types 1 and 2.81 Missplicing was
more common in type 1 disease than type 2 and was seen
only in aff ected muscles, with secondary changes of
muscle tubulation and defective phosphoinositide sig-
nalling. These results were replicated in mouse models,
and the noted changes might be associated with central
nucleation and developmental weakness and hypotonia
in congenital myotonic dystrophy type 1. The rise in
internal nuclei in muscle biopsy samples from adults
with myotonic dystrophy types 1 and 2 could also be
related to this missplicing. Similarly, exon 29 missplicing
of the CaV1.1 calcium channel, involving MBNL1 and
CELF1, was linked functionally to muscle weakness and
altered Ca²+ gating.82 Missplicing in several sarcomeric
muscle proteins, such as LIM domain binding 3 (encoded
by LDB3), myomesin (MYOM1), and myosin heavy
chain 14 non-muscle (MYH14), has also been noted in
patients with myotonic dystrophy type 1 or type 2.12,17,83,84
Data from several animal models suggest that splicing,
foci, and muscle pathological features are separable
events (table 2).85–87 Mbnl1–/– and Mbnl2–/– knockout
mice,85,97 and the Cugbp1 transgenic mouse overexpressing
CELF1,87,102 show aberrant splicing without foci or toxic
mutant RNA. Transgenic mice expressing (CUG)n
repeats (known as HSALR) and Mbnl1–/– knockout mice
both show the same pattern of missplicing as that seen
Transcription factor sequestration:
dysregulation of translation
CNBP RNA processing defect:
reduced protein, dysregulation
(C/CUG)n double-strand RNA:
activation of stress pathways,
dysregulation of translation
DMPK RNA sequestration:
(CUG)/(CAG) small interfering RNA:
RNA interference pathways
mRNA stability dysregulation
mRNA missplicing (CLCN1→myotonia),
Q Q Q QQ
Figure 1: Postulated pathological mechanisms underlying myotonic dystrophy types 1 and 2
Most mechanisms are consistent with the prevailing toxic RNA gain-of-function model and aff ect multiple cellular aspects in the nucleus (blue boxes), the cytoplasm
(grey boxes), or both (blue and grey boxes), including reduced protein function of the mutated genes, missplicing, dysregulation of transcription, protein translation
and turnover, and activation of cellular stress pathways. Both mutant (CTG)n and (CCTG)n expansions in non-coding regions of DMPK and CNBP give rise to
C/CUG-containing transcripts (red) that form stable secondary structures detectable as RNA foci (red circles) in the nucleus and the cytoplasm, and result in reduced
amounts of DMPK and CNBP protein because of DMPK mRNA sequestration or a CNBP pre-mRNA processing defect. Members of the MBNL (green) protein family,
such as MBNL1, are sequestered in ribonuclear foci leading to loss of function and dysregulation of MBNL splice and transcription targets and microRNA metabolism.
Hyperphosphorylation of nuclear and cytoplasmic CELF1 (p-CELF1; salmon) by several protein kinases, including RNA-dependent protein kinase (PKR), leads to
stabilisation of diff erent isoforms, which in turn aff ects alternative splicing, translation, and protein turnover. Inactivation of the translation initiation factor eIF2A
leads to general attenuation of translation. Sequestration of transcription factors and other nuclear factors also contributes to dysregulation of gene expression.
Generation of small interfering RNA from sense (s) and antisense (as) DMPK transcripts might activate RNA interference pathways that lead to wider dysregulation of
mRNA and protein amounts. sDMPK and asDMPK transcripts are subject to repeat-associated non-ATG translation in the polyglutamine (poly[Q]n) reading frame and
possibly others, giving rise to toxic homopolymeric polypeptides that accumulate in the cytoplasm. Although some mechanisms have only been reported in
myotonic dystrophy type 1, theoretically they could also operate in type 2 disease. TF=transcription factor.
www.thelancet.com/neurology Vol 11 October 2012 897
in patients,12,76 although neither mouse model develops
features associated with myotonic dystrophy type 1.66,85
MBNL1 complementation in HSALR mice fails to rescue
the histological abnormalities, but prevents myotonia
and restores adult-splicing patterns,106 suggesting that
muscle degeneration might not be due to MBNL1 loss
alone. The fact that myotonia is less severe in myotonic
dystrophy type 2 compared with type 1 disease, despite a
similar degree of sequestered MBNL1 and misspliced
CLCN1, suggests that spliceopathy is not the only
pathomechanism in the myotonic dystrophies.
Investigations of alternative splicing in myotonic
dystrophy type 1 and type 2, and in other neuromuscular
disorders (Becker, Duchenne, and tibial muscular
dystrophy) indicate that missplicing is not unique to
myotonic dystrophy.107 The myocyte enhancer proteins
MEF2A and MEF2C showed missplicing of exons 4
and 5, respectively, in myotonic dystrophy patients
showing the embryonic isoform. However, similar
splicing diff erences were seen in other neuromuscular
disorders, suggesting that some mechanisms of aberrant
splicing could be compensatory and not primary events,
even in myotonic dystrophy. Similar fi ndings were made
in diff erent mouse models of muscular dystrophy and
muscle injury (including myotonic dystrophy type 1).108
The nuclear and cytoplasmic functions of CELF1 and
MBNL beyond splicing are becoming increasingly clear,
and they include RNA stability and traffi cking and
CELF1 was the fi rst RNA-binding protein implicated
in the pathogenesis of myotonic dystrophy type 1, by
disruption of the splicing of TNNT2, that encodes
troponin T type 2.109 Although it is now commonly
accepted that CELF1 is hyperphosphorylated and
upregulated in myotonic dystrophy type 1,71,98 the issue
remains controversial for type 2 disease.63 In some
reports no changes are indicated,12,110 whereas in other
studies increased steady-state concentrations of CELF1
are seen in patients with myotonic dystrophy type 2,
including in human myoblasts, C2C12 mouse myoblasts
expressing (CCUG)300, and liver and skeletal muscle of
myotonic dystrophy type 2 transgenic mice.111,112
Although MBNL drives splicing towards the adult iso-
form, CELF1 promotes embryonic isoforms of the
aff ected mRNA transcripts. Thus, in myotonic dystrophy
type 1 and type 2, loss of function of MBNL by
sequestration, combined with CELF1 overexpression,
leads to reprogramming of RNA splicing towards an
embryonic state.75 Overexpression of CELF1 in adult
skeletal muscle and cardiac tissue of transgenic mice is
suffi cient to recapitulate molecular, histopathological,
and functional changes typical of type 1 disease.103
Furthermore, CELF1 functions as a key regulator of
mRNA decay113 and has a role in translation initiation in
Overtly normal; aged mice eventually develop altered ion
Cataracts, reduced male fertility, cardiac dysfunction
Myotonia, myopathy, cardiac conduction defects
Dmpk haploinsuffi ciency not primary pathomechanism
Six5 haploinsuffi ciency not primary pathomechanism
Cnbp haploinsuffi ciency recapitulates major aspects of myotonic dystrophy
type 2, can be rescued by Cnbp complementation, no missplicing
Complete defi ciency of Mbnl1 recapitulates major aspects of myotonic
dystrophy type 1, missplicing and misregulation patterns similar to HSALR
Complete defi ciency of Mbnl2 recapitulates specifi c aspects of myotonic
dystrophy type 1, missplicing and misregulation of MBNL target genes
Myotonia, myopathy, cardiomyopathy, missplicing76,85,96
Myotonia, myopathy, missplicing97
Myotonia, myopathy, muscle wasting, (CUG)n foci sequester MBNL,
Myotonia, myopathy, muscle wasting, cardiomyopathy, cardiac
conduction defects, (CUG)n foci sequester MBNL1/stabilise CELF1,
Myotonia, myopathy, (CUG)n foci, missplicing
Expression of (CUG)250 RNA recapitulates major aspects of myotonic dystrophy
type 1, missplicing and misregulation of MBNL target genes
Expression of (CUG)960 RNA recapitulates major aspects of myotonic dystrophy
type 1, missplicing of MBNL and CELF1 target genes
DM300 and DMSXL
Expression of (CUG)n RNA results in mild myotonic dystrophy type 1
phenotype in dose-dependent manner, mild splicing abnormalities
Overexpression of (CUG)5 RNA elicits myotonic dystrophy type 1 phenotype
without foci, with CELF1 upregulation and modest missplicing
Expression of (CCUG)121 RNA recapitulates aspects of myotonic dystrophy
type 2 without missplicing
Overexpression of CELF1 recapitulates aspects of myotonic dystrophy ,
missplicing of CELF1 target genes
Myotonia, myopathy, cardiac conduction defects, missplicing86
DM2-HSAtg-(CCTG)121 Myotonia, myopathy, multisystem pathology, (CCUG)n foci13,101
CELF1 (CUGBP1)Myopathy, cardiomyopathy, cardiac conduction defects, missplicing87,98,102–104
No apparent myotonic dystrophy pathology
Myotonia, myopathy, multisystem pathology, (CCUG)n foci
Increased somatic instability dependent on mismatch repair gene background
Expression of (CCUG)189 RNA recapitulates aspects of myotonic dystrophy
type 2 without missplicing
Table 2: Mouse models of myotonic dystrophy
www.thelancet.com/neurology Vol 11 October 2012
the cytoplasm.61 Upregu lation of CELF1 increases
translation of proteins needed for myogenesis, especially
MEF2A and p21 (cyclin-dependent kinase inhibitor 1A).114
Altered transcriptional regulation
Transcriptome-wide changes in gene expression in
muscle biopsy samples from patients with myotonic
dystrophy type 1 or type 2 have been recorded in various
studies.13,17,115,116 Overall, types 1 and 2 disease had highly
concordant profi les, suggestive of a mutual patho-
physiology.13,115 However, dysregulation of many of the
same genes was shared with other neuromuscular
disorders, indicating that some of the noted changes are
caused by secondary compensatory mechanisms.
Similarly, studies in HSALR and Mbnl1–/– mice also showed
large-scale, shared transcriptional dysregulation, mainly
due to MBNL1 loss.76,96
Inappropriate redistribution (leaching) of the tran s-
cription factor SP1 seems to result in transcriptional
downregulation of CLCN1, among other genes.117
Mislocalisation of the transcription factor SPEN (also
known as SHARP) has been linked to changes in steady-
state concentrations of several mRNA molecules.118 In
myotonic dystrophy type 1, impaired binding to the
CCCTC-binding factor due to methylation of CTCF sites
fl anking the (CTG)n repeats leads to antisense
transcription of the gene DMPK from the regulatory
region of the closest gene, SIX5.39,119
MicroRNA dysregulation and RNA interference
Several muscle-specifi c microRNA molecules (miRs)
have been implicated in myotonic dystrophy type 1 and
type 2.120,121 Molecules that are both downregulated (miR-1,
miR-29b, -miR 29c, and miR-33) and upregulated (miR-
206 and miR-335) have been identifi ed and probably
contribute to the overall myotonic dystrophy phenotype.
Downregulation of miR-1 in cardiac muscle of patients
with type 1 or type 2 disease results in dysregulation of
gap junction protein alpha 1 (GJA1) and the calcium
channel protein CACNA1C.121 Mutant CUG-containing
RNA molecules form double-stranded hairpins which, in
myotonic dystrophy type 1, are subject to cleavage by the
ribonuclease DICER1.122 Although controversial, some
studies have found that processed short (CUG)7 repeats
downregulate RNAs with complementary (CAG)n by
activation of RNA interference pathways.96,122
In myotonic dystrophy type 1, repeat-associated non-ATG
(RAN) translation of the DMPK antisense transcript
gives rise to homopolymeric polyglutamine (poly[Q]n)
peptides in patients’ cells, including skeletal muscle
cells, and in mouse models of type 1 disease. The
contribution of RAN-translated poly(Q)n peptides to the
overall type 1 disease phenotype is currently unclear.123
Double-stranded (C/CUG)n hairpins are recognised by
PKR124 and activate several cellular stress pathways,74
including the innate immune response and interferon
signalling in cataracts.116 PKR activation leads to
inactivation of eukaryotic translation initiation factor 2A
(eIF2A) by phosphorylation at serine 51, which in turn
globally inhibits initiation of translation.125 In muscle of
patients with myotonic dystrophy type 1, a marked
reduction in protein synthesis in vivo has been noted,
suggesting a functional link between reduced protein
translation and muscle wasting,126 and a global trans-
lational defect in type 2 disease has also been seen.74,127,128
A possible consequence of attenuated translation is the
accumulation of untranslated mRNA molecules and
protein-folding intermediates. PKR-dependent forma-
tion of stress granules is induced in CUG-expressing
cells, and translation of the CELF1 target MRG15 is
attenuated.74 MBNL1 might also accumulate in stress
granules by colocalising with the binding protein YB1.129
Prolonged activation of PKR and subsequent eIF2A
inactivation leads to stress in the endoplasmic reticulum,
which has been detected in myotonic dystrophy type 1.130
Endoplasmic reticulum stress results in a block of
translation initiation or apoptosis, both of which might
lead to muscle wasting and weakness.
Roles of DMPK and CNBP
In myotonic dystrophy type 1 and type 2, the expanded
repeats are in untranslated regions of their respective
genes, DMPK and CNBP. Selective eff ects of the
expansions on steady-state mRNA concentrations of the
mutant DMPK allele,131 resulting in reduced amounts of
DMPK protein due to nuclear retention, have been
reported.132,133 Although Dmpk knockout mice do not
initially develop a multisystemic phenotype mimicking
myotonic dystrophy, aged mice eventually develop
specifi c abnormalities.88–90
By contrast, heterozygous Cnbp+/– mice develop
myotonia, cataracts, and muscle pathology without
missplicing of Clcn1, which can be rescued by Cnbp
complementation.95 These data suggest that many
features of myotonic dystrophy can be elicited by
haploinsuffi ciency of CNBP alone. Findings of initial
studies in patients with type 2 disease, mostly done by
in-vitro culture of myoblasts or lymphocytes, suggested
that CNBP mRNA and protein expression are not
aff ected by haploinsuffi ciency.134,135 However, in more
recent studies, evidence indicates reduced concentrations
of CNBP mRNA and protein.110,112,127,128,136 The noted
reductions were attributable to inappropriate processing
of mutant allele pre-mRNA transcripts, suggesting a
processing defect in cis.136
CNBP is an activator of cap-independent translation. It
binds to the internal ribosome entry site (IRES) within
the 5′ untranslated region of target mRNAs and asso-
ciates with actively translating ribosomes. Translation of
ornithine decarboxylase (ODC1) mRNA in myotonic
dystrophy type 2 myoblasts is diminished.128 Over-
expression of CNBP rescues ODC1 translation mediated
www.thelancet.com/neurology Vol 11 October 2012 899
by the IRES site in human patient cells. CNBP also
interacts with terminal oligopyr imidine (TOP) tracts in
the 5′ untranslated regions of mRNA molecules.127
Binding of CNBP to mRNA molecules containing TOP-
tracts was reduced in myotonic dystrophy type 2 muscle,
and a generalised reduction of translation could be
rescued by ectopic expression of CNBP.
Table 2 summarises several important mouse models
of myotonic dystrophy; assessment of 20 diff erent
mouse models has been done by Gomes-Pereira and
colleagues.64 Transgenic mouse models expressing
diff erent lengths of (CUG)n RNA molecules have
established the toxic RNA paradigm as the molecular
culprit in myotonic dystrophy type 1. Although no one
model completely recapitulates all aspects of the
multisystemic phenotype in type 1 or type 2 disease,
diff erent models have helped to clarify distinct aspects of
the overall pathophysiology.
Diagnosis and laboratory fi ndings
Activity of creatine kinase in serum is usually slightly or
moderately raised in patients with myotonic dystrophy
type 1 or type 2, although normal measurements of this
enzyme are frequent in type 2 disease. Increased con-
centrations of liver enzymes, in particular γ-glutamyl-
transferase, are common fi ndings, as is IgG
hypogamma globulinaemia, both for unknown reasons.
Patients with myotonic dystrophy type 2 have augmented
amounts of positive rheumatological serological markers
and high lipid profi les.13 As part of the male
hypogonadism, luteinising hormone and follicle-
stimulating hormone concentrations are frequently
increased, even in sub clinical hypogonadism.1
Before diagnostic genetic testing was available, electro-
myography showing the combination of myotonia and
myopathic changes was pathognomonic for diagnosis.1
However, in mildly aff ected, young adult patients the
myopathic component might be missing, leading to
considerations of myotonia congenita. Findings of nerve
conduction studies are normal. In myotonic dystrophy
type 2, the less prominent and frequently missing, or
conspicuously absent, myotonic component can easily
mislead diag nostic eff orts towards polymyositis.13
Muscle biopsy fi ndings in myotonic dystrophy type 1 are
well established and are more pronounced in distal than
proximal muscle, including a highly increased number
of internal nuclei, sarcoplasmic masses, ring fi bres, and
moderate atrophy of type 1 fi bres in clinically weak
muscles (fi gure 2).1 Histo pathological features in type 2
disease are very diff erent, despite early reports describing
similarities.137 The most characteristic feature of myotonic
dystrophy type 2 is the combination of scattered nuclear
clump fi bres and highly atrophic fi bres consisting of a
subpopulation of type 2A fi bres (fi gure 2).138 Highly
atrophic fi bres are present even before clinical weakness
in proximal lower limb muscles, and initially they were
not recognised because the conventional histochemical
ATPase staining technique to separate fi bres types was
not appropriate for their identifi cation.138,139
Diagnostic DNA testing
In myotonic dystrophy type 1, Southern blot analysis is
the most common technique used to evaluate the
expansion mutation, which has the added advantage of
estimating repeat size. However, this procedure has a
small false-negative rate because of reduced sensitivity
in cases of extreme somatic heterogeneity. In myotonic
dystrophy type 2, a combination of genotyping assays is
used across the genomic sequence of the expected
expansion repeat; if two normal-sized alleles are
detected, the diagnosis of type 2 disease can be excluded.
If just one normal-sized allele is detected, the sample
either contains a myotonic dystrophy type 2 mutation
on the other allele that is resistant to PCR amplifi cation
or two normal alleles of the same size are present, a
fi nding that arises in about 10% of the healthy
Figure 2: Diff erential histopathological features on muscle biopsy
In myotonic dystrophy type 1, the characteristic feature detected on conventional haematoxylin and eosin stain
(A) is fi bre size variation and an increased number of internal nuclei in the fi bres (arrow) in distal muscles. On
immunohistochemical fi bre typing (B), slow type 1 fi bres (brown) are on average smaller than fast type 2 fi bres
(blue). In myotonic dystrophy type 2, the early fi nding at diagnosis on haematoxylin and eosin staining (C) is an
increased number of small atrophic fi bres containing, almost exclusively, nuclei (so-called nuclear clump fi bres),
even in asymptomatic proximal muscles (arrow). On immunohistochemical fi bre typing (D), a subpopulation of
fast type 2 fi bres (brown) is highly atrophic (arrow). Both nuclear clump fi bres and other type 2 fi bres are atrophic.
Original magnifi cation ×400.
www.thelancet.com/neurology Vol 11 October 2012
population. In cases of an apparently homozygous
normal allele, testing is continued with repeat-primed
PCR specifi c for the type 2 disease expansion repeat.10,30,49
Used together, these techniques provide high sensitivity
and specifi city. Diagnostic laboratories need to have
access to more than one methodological approach
because some samples will show inconclusive fi ndings
with just one method. Complementary techniques to
clarify equivocal results include Southern blots and
fl uorescence in situ hybrid isation
chromogenic in situ hybridisation (CISH). If leucocyte
DNA samples give inconclusive results, then DNA from
muscle tissue might be a good alternative.13
Imaging of muscle and brain
In both types of myotonic dystrophy, fatty degenerative
changes in muscles, detectable by MRI, develop grossly
in parallel with clinical muscle weakness and atrophy.13
However, the pattern of more pronounced involvement
of lower limb muscles in myotonic dystrophy type 1,
versus less involvement in type 2 disease, is clearly
diff erent (fi gure 3). In type 1 disease, initial changes are
seen in the soleus and medial gastrocnemius; these
muscles in the lower leg are replaced completely by fatty
infi ltration (degenerative changes), sometimes even
before major changes are noted in the upper leg near the
thigh. In myotonic dystrophy type 2, early muscular
changes develop in the anterior vastus group of thigh
muscles, with relative sparing of the rectus femoris. At
this stage, the lower leg muscle might appear completely
normal by imaging.13
In congenital, childhood-onset, and advanced adult-
onset myotonic dystrophy type 1, widespread white-
matter changes are present in the brain, with grey-matter
alterations and atrophy seen less frequently and to a
lesser extent. In patients with type 2 disease, brain MRI
fi ndings can be entirely normal. However, in advanced
stages or more severe cases, diff use white-matter changes
might be less pronounced than and diff erent to those in
myotonic dystrophy type 1.13,26,140
Clinical complications and management
The delay between onset of fi rst symptoms and correct
diagnosis is usually very long, on average more than
5 years for myotonic dystrophy type 1 and greater than
14 years for patients with type 2 disease.13 The long delay
with diagnosis of myotonic dystrophy type 2 is mainly
attributable to scant awareness of the disease by
clinicians, which causes unnecessary diffi culties for
patients trying to manage their lives, mental stress, and
anguish with uncertainty of prognosis and treatment.
Cardiac arrhythmias are a major cause of mortality in
myotonic dystrophy type 1 and, thus, are an important
feature that needs monitoring and treatment.18,20 How-
ever, in myotonic dystrophy type 2, cardiac deaths occur
with low frequency.141 Prompt referral for cardiology
consultation and therapeutic intervention are indicated
when signs suggest cardiac dysfunction, measures
show prolonged PR interval or QRS, and atrial
fi brillation or fl utter is recorded. Serial electro-
cardiogram (ECG) monitoring is needed.142 Cardio-
myopathy is infrequent, whereas coronary heart disease
Figure 3: Muscle imaging
(A) CT sections of lower legs (upper) and thighs (lower) in a 32-year-old man with myotonic dystrophy type 1. He also had frontal baldness, weak fi ngers, grip
myotonia, and thin lower legs. The most evident changes after muscle weakness were fi rst noted clinically in the medial gastrocnemius and the soleus muscles
(arrows). (B) MRI sections of lower leg (upper) and thigh (lower) in a 61-year-old woman with myotonic dystrophy type 2. She also had myalgia, proximal weakness
since age 55 years (grade 4), a mild increase in creatine kinase to 380 IU/L, and myotonia on electromyography, but no clinical myotonia and no cataracts. No changes
are seen in the lower leg muscles; instead, fatty degenerative changes are present in the vastus lateralis muscles (arrows) in the thighs. Note also the overall reduced
volume of thigh muscles.
www.thelancet.com/neurology Vol 11 October 2012 901
is a common problem in patients with myotonic
dystrophy type 2.
Cataracts need conventional surgical treatment.
Anaesthetic risk is increased in patients with myotonic
dystrophy type 1, with prolonged post-anaesthetic
respiratory recovery and increased frequency of
pneumonia.143,144 Again, type 2 disease is diff erent and no
increased risk has been encountered.145
Myotonia rarely restricts activities of daily life. However,
myotonic stiff ness is usually mixed with myalgic pains
and, therefore, trials with mexiletine or fl ecainide (two
doses of 50–100 mg) or propafenone (two doses of
150–300 mg) can be considered.13,142 Hormonal changes
in pregnancy can worsen myotonia, myalgic stiff ness,
and cataracts, although the reasons are uncertain, and
these eff ects are reported more consistently in myotonic
dystrophy type 2.13
Fatigue and daytime sleepiness can be severe in
patients with myotonic dystrophy type 1, and the eff ects
of treatment have been modest.
In patients with myotonic dystrophy types 1 or 2,
monitoring of lipid profi les and assessment of oral glucose
tolerance are advised.142,146 Atherosclerosis is frequent in
individuals with type 2 disease, and an increased frequency
of adverse reactions to statin treatment is a challenge, not
least because a statin-related reaction can be masked in
patients with myotonic dystrophy type 2 and myalgia.13,146
Some individuals with type 2 disease tolerate statins
without severe adverse reactions, but if side-eff ects
develop, treatment has to be discontinued; moderate rises
in cholesterol (<8 mmol/L) in older patients with myotonic
dystrophy might not need treatment.13
Medical treatment of muscle pain has been largely
unsuccessful. Patients with severe disabling pain can
be referred to a pain specialist. Hypothyroidism and
gonadal failure are treated with hormone replacement
when needed. If drugs for erectile dysfunction are
considered, concentrations of testosterone should be
checked fi rst. Mildly raised amounts of liver enzymes
(eg, γ-glutamyltransferase) are common in patients with
myotonic dystrophy and further liver investigations are
usually not needed.146
Cancer risk in patients with myotonic dystrophy is
uncertain. Epitheliomas and pilomatricomas have been
reported in patients with type 1 disease;1 however, only in
recent studies of large registries has an average overall
twofold increase in relative risk for various cancers been
confi rmed for patients with a clinical diagnosis of
myotonic dystrophy; for some cancers (endometrium,
ovary, brain, and colon) risk is as high as sevenfold.147
This augmented risk seems to be associated with female
sex in patients with myotonic dystrophy type 1 and is not
correlated with (CTG)n expansion size.148
At present, no eff ective treatment is available for myo-
tonic dystrophy types 1 and 2. Experimental approaches
target elimination of toxic repeat transcripts in type 1
disease models.64,149 Powerful and stable antisense
oligonucleotides are available—usually complementary
to the (CUG)n expansion in myotonic dystrophy type 1—
that reduce transcripts from the mutant DMPK allele,
leading to a decrease in ribonuclear foci without ne-
cessarily aff ecting the expression of DMPK protein.150,151
Binding of antisense oligonucleotides to the expansion
repeat induces degradation of RNA. In mouse models
of type 1 disease, local delivery of antisense
oligonucleotides to muscle tissue has been completed,
with good results, but optimisation of treatment is
needed because current procedures allow effi cient
delivery of antisense oligo nucleotides in the liver or the
kidney, but they cannot deliver effi cient amounts in
muscle tissue. Morpholino injections into the tail vein
in a mouse model eff ectively reduced myotonia within
4–5 weeks.150 Alternative approaches64,149 targeting down-
stream changes include upregulation of MBNL
activity,152 downregulation of CELF1 activity,71,153 and
reversal of specifi c missplicing events.80 Since only a few
other genes in the human genome have long CCTG
stretches, antisense oligonucleotides directed at
(CCUG)n expan sion repeats in myotonic dystrophy
type 2 should be fairly easy to design if procedures in
type 1 disease are successful.
20 years have passed since the (CTG)n repeat expansion
mutation was discovered in patients with myotonic
dystrophy type 1, and 11 years ago the (CCTG)n mutation
was identifi ed in type 2 disease. Although much has
been learned within this period, many challenges
remain. Emerging data indicate that molecular
pathomechanisms are much more complex than could
have been envisioned when the respective mutations
were fi rst identifi ed. Promising experimental treat-
ments are emerging. However, for ultimately eff ective
thera peutic strategies, a better understanding of the
patho physiology and mechanisms of DNA instability is
essential. RNA toxicity clearly has a major role, yet
spliceopathy alone does not seem to fully account for all
Search strategy and selection criteria
We searched PubMed with the terms “myotonic dystrophy”,
“myotonic dystrophy type 1”, and “myotonic dystrophy
type 2” for papers published from 1992 to May, 2012, with
focus on advances made over the past 10 years. We also
manually searched our own fi les and reference lists of
published work to identify further relevant papers. Only
papers published in English were reviewed. Because of space
constraints we were unable to include all pertinent papers
published on this topic. The fi nal reference list was generated
on the basis of originality and relevance to the broad scope of
www.thelancet.com/neurology Vol 11 October 2012
aspects of the multisystemic myotonic dystrophy
pheno type. The resident genes (containing the
mutations), especially for type 2 disease, might also
have an important role. Other pathomechanisms,
consistent with the toxic RNA model, probably entail
regulation of gene expression and translation, and
various cellular stress pathways, and extend beyond the
nucleus to the cytoplasm. Going forward, understanding
the extent to which these mechanisms account for the
overall myotonic dystrophy phenotype will be
important. If we have learned anything from myotonic
dystrophy, it is to keep an open mind because, in the
words of Peter Harper, “anything that can go wrong
does go wrong in myotonic dystrophy”.1
BU initiated the project, but otherwise both authors contributed equally
to the literature search, preparation of fi gures, and writing and revising
of the paper.
Confl icts of interest
We declare that we have no confl icts of interest.
Research in BU’s group has been supported by the following
foundations: Medicinska Undestödsföreningen Liv och Hälsa rs; Medical
Foundations of Vasa Central Hospital and Pirkanmaan Hospital District;
and Folkhälsan Foundation rs. RK thanks Linda Bachinski and other
members of the Krahe lab, and Andrew Link for fruitful discussions.
Research in RK’s group has been supported by MDA, NIAMS, and the
Kleberg Foundation for Genetics Research.
1 Harper PS. Myotonic dystrophy, 3rd edn. London: WB Saunders, 2001.
2 Thornton CA, Johnson K, Moxley RT III. Myotonic dystrophy
patients have larger CTG expansions in skeletal muscle than in
leukocytes. Ann Neurol 1994; 35: 104–07.
3 Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic
myopathy: a new dominant disorder with myotonia, muscle
weakness, and cataracts. Neurology 1994; 44: 1448–52.
4 Udd B, Krahe R, Wallgren-Pettersson C, et al. Proximal myotonic
dystrophy: a family with autosomal dominant muscular dystrophy,
cataracts, hearing loss and hypogonadism: heterogeneity of
proximal myotonic syndromes? Neuromuscul Disord 1997; 7: 217–28.
5 Ranum LP, Rasmussen PF, Benzow KA, et al. Genetic mapping
of a second myotonic dystrophy locus. Nat Genet 1998;
6 Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of
myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at
the 3′ end of a transcript encoding a protein kinase family
member. Cell 1992; 68: 799–808.
7 Fu YH, Pizzuti A, Fenwick RG Jr, et al. An unstable triplet repeat in
a gene related to myotonic muscular dystrophy. Science 1992;
8 Mahadevan M, Tsilfi dis C, Sabourin L, et al. Myotonic dystrophy
mutation: an unstable CTG repeat in the 3′ untranslated region of
the gene. Science 1992; 255: 1253–55.
9 Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy
type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science
2001; 293: 864–67.
10 Bachinski LL, Udd B, Meola G, et al. Confi rmation of the type 2
myotonic dystrophy (CCTG)n expansion mutation in patients with
proximal myotonic myopathy/proximal myotonic dystrophy of
diff erent European origins: a single shared haplotype indicates an
ancestral founder eff ect. Am J Hum Genet 2003; 73: 835–48.
11 Mankodi A, Teng-Umnuay P, Krym M, et al. Ribonuclear
inclusions in skeletal muscle in myotonic dystrophy types 1 and 2.
Ann Neurol 2003; 54: 760–68.
12 Lin X, Miller JW, Mankodi A, et al. Failure of MBNL1-dependent
postnatal splicing transitions in myotonic dystrophy.
Hum Mol Genet 2006; 15: 2087–97.
13 Udd B, Meola G, Krahe R, et al. Myotonic dystrophy type 2 (DM2)
and related disorders report of the 180th ENMC workshop
including guidelines on diagnostics and management
3–5 December 2010, Naarden, The Netherlands.
Neuromuscul Disord 2011; 21: 443–50.
14 Suominen T, Bachinski LL, Auvinen S, et al. Population frequency
of myotonic dystrophy: higher than expected frequency of
myotonic dystrophy type 2 (DM2) mutation in Finland.
Eur J Hum Genet 2011; 19: 776–82.
15 Suominen T, Schoser B, Raheem O, et al. High frequency of
co-segregating CLCN1 mutations among myotonic dystrophy type 2
patients from Finland and Germany. J Neurol 2008; 255: 1731–36.
16 Arsenault ME, Prevost C, Lescault A, et al. Clinical characteristics
of myotonic dystrophy type 1 patients with small CTG expansions.
Neurology 2006; 66: 1248–50.
17 Vihola A, Bachinski LL, Sirito M, et al. Diff erences in aberrant
expression and splicing of sarcomeric proteins in the myotonic
dystrophies DM1 and DM2. Acta Neuropathol 2010; 119: 465–79.
18 Mathieu J, Allard P, Potvin L, et al. A 10-year study of mortality in
a cohort of patients with myotonic dystrophy. Neurology 1999;
19 Logigian EL, Blood CL, Dilek N, et al. Quantitative analysis of the
“warm-up” phenomenon in myotonic dystrophy type 1.
Muscle Nerve 2005; 32: 35–42.
20 Groh WJ, Groh MR, Saha C, et al. Electrocardiographic
abnormalities and sudden death in myotonic dystrophy type 1.
N Engl J Med 2008; 358: 2688–97.
21 Garrott HM, Walland MJ, O’Day J. Recurrent posterior capsular
opacifi cation and capsulorhexis contracture after cataract surgery
in myotonic dystrophy. Clin Experiment Ophthalmol 2004;
22 Ashizawa T, Sarkar PS. Myotonic dystrophy types 1 and 2.
Handb Clin Neurol 2011; 101: 193–237.
23 Winblad S, Lindberg C, Hansen S. Temperament and character in
patients with classical myotonic dystrophy type 1 (DM-1).
Neuromuscul Disord 2005; 15: 287–92.
24 van der Werf S, Kalkman J, Bleijenberg G, et al. The relation
between daytime sleepiness, fatigue, and reduced motivation in
patients with adult onset myotonic dystrophy.
J Neurol Neurosurg Psychiatry 2003; 74: 138–39.
25 van Engelen BG, Eymard B, Wilcox D. 123rd ENMC International
Workshop: management and therapy in myotonic dystrophy,
6–8 February 2004, Naarden, The Netherlands. Neuromuscul Disord
2005; 15: 389–94.
26 Minnerop M, Weber B, Schoene-Bake JC, et al. The brain in
myotonic dystrophy 1 and 2: evidence for a predominant white
matter disease. Brain 2011; 134: 3527–43.
27 Ronnblom A, Forsberg H, Danielsson A. Gastrointestinal
symptoms in myotonic dystrophy. Scand J Gastroenterol 1996;
28 Angeard N, Jacquette A, Gargiulo M, et al. A new window on
neurocognitive dysfunction in the childhood form of myotonic
dystrophy type 1 (DM1). Neuromuscul Disord 2011; 21: 468–76.
29 Echenne B, Rideau A, Roubertie A, et al. Myotonic dystrophy type I
in childhood: long-term evolution in patients surviving the neonatal
period. Eur J Paediatr Neurol 2008; 12: 210–23.
30 Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2:
molecular, diagnostic and clinical spectrum. Neurology 2003;
31 George A, Schneider-Gold C, Zier S, et al. Musculoskeletal pain in
patients with myotonic dystrophy type 2. Arch Neurol 2004; 61: 1938–42.
32 Suokas KI, Haanpaa M, Kautiainen H, et al. Pain in patients with
myotonic dystrophy type 2: a postal survey in fi nland. Muscle Nerve
2012; 45: 70–4.
33 Auvinen S, Suominen T, Hannonen P, et al. Myotonic dystrophy
type 2 found in two of sixty-three persons diagnosed as having
fi bromyalgia. Arthritis Rheum 2008; 58: 3627–31.
34 Morales F, Couto JM, Higham CF, et al. Somatic instability of the
expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable
quantitative trait and modifi er of disease severity. Hum Mol Genet 2012;
published online May 16. DOI:10.1093/hmg/dds185.
35 Salehi LB, Bonifazi E, Stasio ED, et al. Risk prediction for clinical
phenotype in myotonic dystrophy type 1: data from 2,650 patients.
Genet Test 2007; 11: 84–90.
www.thelancet.com/neurology Vol 11 October 2012 903
36 Savic D, Rakocvic-Stojanovic V, Keckarevic D, et al. 250 CTG repeats
in DMPK is a threshold for correlation of expansion size and age at
onset of juvenile-adult DM1. Hum Mutat 2002; 19: 131–39.
37 Wong LJ, Ashizawa T, Monckton DG, et al. Somatic heterogeneity
of the CTG repeat in myotonic dystrophy is age and size dependent.
Am J Hum Genet 1995; 56: 114–22.
38 Monckton DG, Wong LJ, Ashizawa T, et al. Somatic mosaicism,
germline expansions, germline reversions and intergenerational
reductions in myotonic dystrophy males: small pool PCR analyses.
Hum Mol Genet 1995; 4: 1–8.
39 Lopez Castel A, Nakamori M, Tome S, et al. Expanded CTG repeat
demarcates a boundary for abnormal CpG methylation in myotonic
dystrophy patient tissues. Hum Mol Genet 2011; 20: 1–15.
40 Higham CF, Morales F, Cobbold CA, et al. High levels of somatic
DNA diversity at the myotonic dystrophy type 1 locus are driven by
ultra-frequent expansion and contraction mutations.
Hum Mol Genet 2012; 21: 2450–63.
41 Braida C, Stefanatos RK, Adam B, et al. Variant CCG and GGC
repeats within the CTG expansion dramatically modify mutational
dynamics and likely contribute toward unusual symptoms in some
myotonic dystrophy type 1 patients. Hum Mol Genet 2010;
42 Axford MM, Lopez-Castel A, Nakamori M, et al. Replacement of the
myotonic dystrophy type 1 CTG repeat with ‘non-CTG repeat’
insertions in specifi c tissues. J Med Genet 2011; 48: 438–43.
43 Pearson CE, Edamura KN, Cleary JD. Repeat instability:
mechanisms of dynamic mutations. Nat Rev Genet 2005; 6: 729–42.
44 Ashizawa T, Dunne PW, Ward PA, et al. Eff ects of the sex of
myotonic dystrophy patients on the unstable triplet repeat in their
aff ected off spring. Neurology 1994; 44: 120–22.
45 Ashizawa T, Anvret M, Baiget M, et al. Characteristics of
intergenerational contractions of the CTG repeat in myotonic
dystrophy. Am J Hum Genet 1994; 54: 414–23.
46 Martorell L, Gamez J, Cayuela ML, et al. Germline mutational
dynamics in myotonic dystrophy type 1 males: allele length and age
eff ects. Neurology 2004; 62: 269–74.
47 Liquori CL, Ikeda Y, Weatherspoon M, et al. Myotonic dystrophy
type 2: human founder haplotype and evolutionary conservation of
the repeat tract. Am J Hum Genet 2003; 73: 849–62.
48 Bachinski LL, Czernuszewicz T, Ramagli LS, et al. Premutation
allele pool in myotonic dystrophy type 2. Neurology 2009; 72: 490–97.
49 Sallinen R, Vihola A, Bachinski LL, et al. New methods for
molecular diagnosis and demonstration of the (CCTG)n mutation in
myotonic dystrophy type 2 (DM2). Neuromuscul Disord 2004;
50 Krahe R, Bachinski LL, Udd B. Myotonic dystrophy type 2: clinical
and genetic aspects. In: Wells RD, Ashizawa T, eds. Genetic
instabilities and neurological diseases: Oxford: Elsevier, 2006:
51 Jansen G, Willems P, Coerwinkel M, et al. Gonosomal mosaicism
in myotonic dystrophy patients: involvement of mitotic events in
(CTG)n repeat variation and selection against extreme expansion in
sperm. Am J Hum Genet 1994; 54: 575–85.
52 Yamagata H, Nakagawa M, Johnson K, et al. Further evidence for a
major ancient mutation underlying myotonic dystrophy from
linkage disequilibrium studies in the Japanese population.
J Hum Genet 1998; 43: 246–49.
53 Ashizawa T, Epstein HF. Ethnic distribution of myotonic dystrophy
gene. Lancet 1991; 338: 642–43.
54 Basu P, Majumder PP, Roychoudhury S, et al. Haplotype analysis of
genomic polymorphisms in and around the myotonic dystrophy
locus in diverse populations of India. Hum Genet 2001; 108: 310–17.
55 Krahe R, Eckhart M, Ogunniyi AO, et al. De novo myotonic
dystrophy mutation in a Nigerian kindred. Am J Hum Genet 1995;
56 Goldman A, Ramsay M, Jenkins T. Ethnicity and myotonic
dystrophy: a possible explanation for its absence in sub-Saharan
Africa. Ann Hum Genet 1996; 60: 57–65.
57 Schoser BG, Kress W, Walter MC, et al. Homozygosity for CCTG
mutation in myotonic dystrophy type 2. Brain 2004; 127: 1868–77.
58 Saito T, Amakusa Y, Kimura T, et al. Myotonic dystrophy type 2 in
Japan: ancestral origin distinct from Caucasian families.
Neurogenetics 2008; 9: 61–63.
59 Neville CE, Mahadevan MS, Barcelo JM, et al. High resolution
genetic analysis suggests one ancestral predisposing haplotype for
the origin of the myotonic dystrophy mutation. Hum Mol Genet
1994; 3: 45–51.
60 Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy.
Biochem Soc Trans 2009; 37: 1281–86.
61 Schneider-Gold C, Timchenko LT. CCUG repeats reduce the rate of
global protein synthesis in myotonic dystrophy type 2. Rev Neurosci
2010; 21: 19–28.
62 Klein AF, Gasnier E, Furling D. Gain of RNA function in
pathological cases: focus on myotonic dystrophy. Biochimie 2011;
63 Sicot G, Gourdon G, Gomes-Pereira M. Myotonic dystrophy, when
simple repeats reveal complex pathogenic entities: new fi ndings
and future challenges. Hum Mol Genet 2011; 20: R116–23.
64 Gomes-Pereira M, Cooper TA, Gourdon G. Myotonic dystrophy
mouse models: towards rational therapy development.
Trends Mol Med 2011; 17: 506–17.
65 Amack JD, Mahadevan MS. The myotonic dystrophy expanded
CUG repeat tract is necessary but not suffi cient to disrupt C2C12
myoblast diff erentiation. Hum Mol Genet 2001; 10: 1879–87.
66 Mankodi A, Logigian E, Callahan L, et al. Myotonic dystrophy in
transgenic mice expressing an expanded CUG repeat. Science 2000;
67 Osborne RJ, Thornton CA. RNA-dominant diseases.
Hum Mol Genet 2006; 15 (spec no 2): R162–69.
68 Fernandez-Costa JM, Llamusi MB, Garcia-Lopez A, et al. Alternative
splicing regulation by Muscleblind proteins: from development to
disease. Biol Rev Camb Philos Soc 2011; 86: 947–58.
69 Jiang H, Mankodi A, Swanson MS, et al. Myotonic dystrophy type 1
is associated with nuclear foci of mutant RNA, sequestration of
muscleblind proteins and deregulated alternative splicing in
neurons. Hum Mol Genet 2004; 13: 3079–88.
70 Fardaei M, Rogers MT, Thorpe HM, et al. Three proteins, MBNL,
MBLL and MBXL, co-localize in vivo with nuclear foci of
expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet
2002; 11: 805–14.
71 Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased
steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to
PKC-mediated hyperphosphorylation. Mol Cell 2007; 28: 68–78.
72 Salisbury E, Sakai K, Schoser B, et al. Ectopic expression of cyclin
D3 corrects diff erentiation of DM1 myoblasts through activation of
RNA CUG-binding protein, CUGBP1. Exp Cell Res 2008;
73 Jin J, Wang GL, Salisbury E, et al. GSK3β-cyclin D3-CUGBP1-eIF2
pathway in aging and in myotonic dystrophy. Cell Cycle 2009;
74 Huichalaf C, Sakai K, Jin B, et al. Expansion of CUG RNA repeats
causes stress and inhibition of translation in myotonic dystrophy 1
(DM1) cells. FASEB J 2010; 24: 3706–19.
75 Kalsotra A, Xiao X, Ward AJ, et al. A postnatal switch of CELF and
MBNL proteins reprograms alternative splicing in the developing
heart. Proc Natl Acad Sci USA 2008; 105: 20333–38.
76 Du H, Cline MS, Osborne RJ, et al. Aberrant alternative splicing
and extracellular matrix gene expression in mouse models of
myotonic dystrophy. Nat Struct Mol Biol 2010; 17: 187–93.
77 Charlet-B N, Savkur RS, Singh G, et al. Loss of the muscle-specifi c
chloride channel in type 1 myotonic dystrophy due to misregulated
alternative splicing. Mol Cell 2002; 10: 45–53.
78 Lueck JD, Mankodi A, Swanson MS, et al. Muscle chloride channel
dysfunction in two mouse models of myotonic dystrophy.
J Gen Physiol 2007; 129: 79–94.
79 Mankodi A, Takahashi MP, Jiang H, et al. Expanded CUG repeats
trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and
hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell
2002; 10: 35–44.
80 Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1
splicing eliminates chloride channelopathy and myotonia in
mouse models of myotonic dystrophy. J Clin Invest 2007;
81 Fugier C, Klein AF, Hammer C, et al. Misregulated alternative
splicing of BIN1 is associated with T tubule alterations and muscle
weakness in myotonic dystrophy. Nat Med 2011; 17: 720–25.
www.thelancet.com/neurology Vol 11 October 2012
82 Tang ZZ, Yarotskyy V, Wei L, et al. Muscle weakness in myotonic
dystrophy associated with misregulated splicing and altered gating
of CaV1.1 calcium channel. Hum Mol Genet 2012; 21: 1312–24.
83 Koebis M, Ohsawa N, Kino Y, et al. Alternative splicing of
myomesin 1 gene is aberrantly regulated in myotonic dystrophy
type 1. Genes Cells 2011; 16: 961–72.
84 Rinaldi F, Terracciano C, Pisani V, et al. Aberrant splicing and
expression of the non muscle myosin heavy-chain gene MYH14 in
DM1 muscle tissues. Neurobiol Dis 2012; 45: 264–71.
85 Kanadia RN, Johnstone KA, Mankodi A, et al. A muscleblind
knockout model for myotonic dystrophy. Science 2003;
86 Mahadevan MS, Yadava RS, Yu Q, et al. Reversible model of RNA
toxicity and cardiac conduction defects in myotonic dystrophy.
Nat Genet 2006; 38: 1066–70.
87 Timchenko NA, Patel R, Iakova P, et al. Overexpression of CUG
triplet repeat-binding protein, CUGBP1, in mice inhibits
myogenesis. J Biol Chem 2004; 279: 13129–39.
88 Jansen G, Groenen PJ, Bachner D, et al. Abnormal myotonic
dystrophy protein kinase levels produce only mild myopathy in
mice. Nat Genet 1996; 13: 316–24.
89 Reddy S, Smith DB, Rich MM, et al. Mice lacking the myotonic
dystrophy protein kinase develop a late onset progressive myopathy.
Nat Genet 1996; 13: 325–35.
90 Berul CI, Maguire CT, Gehrmann J, et al. Progressive
atrioventricular conduction block in a mouse myotonic dystrophy
model. J Interv Card Electrophysiol 2000; 4: 351–58.
91 Sarkar PS, Appukuttan B, Han J, et al. Heterozygous loss of Six5 in
mice is suffi cient to cause ocular cataracts. Nat Genet 2000;
92 Klesert TR, Cho DH, Clark JI, et al. Mice defi cient in Six5 develop
cataracts: implications for myotonic dystrophy. Nat Genet 2000;
93 Wakimoto H, Maguire CT, Sherwood MC, et al. Characterization of
cardiac conduction system abnormalities in mice with targeted
disruption of Six5 gene. J Interv Card Electrophysiol 2002; 7: 127–35.
94 Sarkar PS, Paul S, Han J, et al. Six5 is required for spermatogenic
cell survival and spermiogenesis. Hum Mol Genet 2004; 13: 1421–31.
95 Chen W, Wang Y, Abe Y, et al. Haploinsuff ciency for Znf9 in Znf9+/-
mice is associated with multiorgan abnormalities resembling
myotonic dystrophy. J Mol Biol 2007; 368: 8–17.
96 Osborne RJ, Lin X, Welle S, et al. Transcriptional and
post-transcriptional impact of toxic RNA in myotonic dystrophy.
Hum Mol Genet 2009; 18: 1471–81.
97 Hao M, Akrami K, Wei K, et al. Muscleblind-like 2 (Mbnl2)
-defi cient mice as a model for myotonic dystrophy. Dev Dyn 2008;
98 Wang GS, Kearney DL, De Biasi M, et al. Elevation of RNA-binding
protein CUGBP1 is an early event in an inducible heart-specifi c
mouse model of myotonic dystrophy. J Clin Invest 2007;
99 Orengo JP, Chambon P, Metzger D, et al. Expanded CTG repeats
within the DMPK 3′ UTR causes severe skeletal muscle wasting in
an inducible mouse model for myotonic dystrophy.
Proc Natl Acad Sci USA 2008; 105: 2646–51.
100 Seznec H, Lia-Baldini AS, Duros C, et al. Transgenic mice carrying
large human genomic sequences with expanded CTG repeat mimic
closely the DM CTG repeat intergenerational and somatic
instability. Hum Mol Genet 2000; 9: 1185–94.
101 Krahe R, Sirito M, Wojciechowska M, et al. Mouse models for
myotonic dystrophy type 2 (DM2) lacking aberrant splicing
implicate novel cytoplasmic pathomechanisms. Med Genetik 2009;
102 Ho TH, Bundman D, Armstrong DL, et al. Transgenic mice
expressing CUG-BP1 reproduce splicing mis-regulation observed
in myotonic dystrophy. Hum Mol Genet 2005; 14: 1539–47.
103 Koshelev M, Sarma S, Price RE, et al. Heart-specifi c
overexpression of CUGBP1 reproduces functional and molecular
abnormalities of myotonic dystrophy type 1. Hum Mol Genet 2010;
104 Ward AJ, Rimer M, Killian JM, et al. CUGBP1 overexpression in
mouse skeletal muscle reproduces features of myotonic dystrophy
type 1. Hum Mol Genet 2010; 19: 3614–22.
105 van den Broek WJ, Nelen MR, Wansink DG, et al. Somatic
expansion behaviour of the (CTG)n repeat in myotonic dystrophy
knock-in mice is diff erentially aff ected by Msh3 and Msh6
mismatch-repair proteins. Hum Mol Genet 2002; 11: 191–98.
106 Kanadia RN, Shin J, Yuan Y, et al. Reversal of RNA missplicing
and myotonia after muscleblind overexpression in a mouse
poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci USA
2006; 103: 11748–53.
107 Bachinski LL, Sirito M, Bohme M, et al. Altered MEF2 isoforms in
myotonic dystrophy and other neuromuscular disorders.
Muscle Nerve 2010; 42: 856–63.
108 Orengo JP, Ward AJ, Cooper TA. Alternative splicing dysregulation
secondary to skeletal muscle regeneration. Ann Neurol 2011;
109 Philips AV, Timchenko LT, Cooper TA. Disruption of splicing
regulated by a CUG-binding protein in myotonic dystrophy.
Science 1998; 280: 737–41.
110 Pelletier R, Hamel F, Beaulieu D, et al. Absence of a diff erentiation
defect in muscle satellite cells from DM2 patients. Neurobiol Dis
2009; 36: 181–90.
111 Salisbury E, Schoser B, Schneider-Gold C, et al. Expression of
RNA CCUG repeats dysregulates translation and degradation of
proteins in myotonic dystrophy 2 patients. Am J Pathol 2009;
112 Jones K, Jin B, Polina I, et al. RNA foci, CUGBP1, and ZNF9 are the
primary targets of the mutant CUG and CCUG repeats expanded in
myotonic dystrophies type 1 and type 2. Am J Pathol 2011;
113 Lee JE, Lee JY, Wilusz J, et al. Systematic analysis of cis-elements in
unstable mRNAs demonstrates that CUGBP1 is a key regulator of
mRNA decay in muscle cells. PLoS One 2010; 5: e11201.
114 Timchenko NA, Cai ZJ, Welm AL, et al. RNA CUG repeats
sequester CUGBP1 and alter protein levels and activity of CUGBP1.
J Biol Chem 2001; 276: 7820–26.
115 Botta A, Vallo L, Rinaldi F, et al. Gene expression analysis in
myotonic dystrophy: indications for a common molecular
pathogenic pathway in DM1 and DM2. Gene Expr 2007;
116 Rhodes JD, Lott MC, Russell SL, et al. Activation of the innate
immune response and interferon signalling in myotonic dystrophy
type 1 and type 2 cataracts. Hum Mol Genet 2012; 21: 852–62.
117 Ebralidze A, Wang Y, Petkova V, et al. RNA leaching of transcription
factors disrupts transcription in myotonic dystrophy. Science 2004;
118 Dansithong W, Jog SP, Paul S, et al. RNA steady-state defects in
myotonic dystrophy are linked to nuclear exclusion of SHARP.
EMBO Rep 2011; 12: 735–42.
119 Cho DH, Thienes CP, Mahoney SE, et al. Antisense transcription
and heterochromatin at the DM1 CTG repeats are constrained by
CTCF. Mol Cell 2005; 20: 483–89.
120 Perbellini R, Greco S, Sarra-Ferraris G, et al. Dysregulation and
cellular mislocalization of specifi c miRNAs in myotonic dystrophy
type 1. Neuromuscul Disord 2011; 21: 81–88.
121 Rau F, Freyermuth F, Fugier C, et al. Misregulation of miR-1
processing is associated with heart defects in myotonic dystrophy.
Nat Struct Mol Biol 2011; 18: 840–45.
122 Krol J, Fiszer A, Mykowska A, et al. Ribonuclease dicer cleaves
triplet repeat hairpins into shorter repeats that silence specifi c
targets. Mol Cell 2007; 25: 575–86.
123 Zu T, Gibbens B, Doty NS, et al. Non-ATG-initiated translation
directed by microsatellite expansions. Proc Natl Acad Sci USA 2011;
124 Tian B, White RJ, Xia T, et al. Expanded CUG repeat RNAs form
hairpins that activate the double-stranded RNA-dependent protein
kinase PKR. RNA 2000; 6: 79–87.
125 Ron D, Walter P. Signal integration in the endoplasmic reticulum
unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519–29.
126 Halliday D, Ford GC, Edwards RH, et al. In vivo estimation of
muscle protein synthesis in myotonic dystrophy. Ann Neurol 1985;
127 Huichalaf C, Schoser B, Schneider-Gold C, et al. Reduction of the
rate of protein translation in patients with myotonic dystrophy 2.
J Neurosci 2009; 29: 9042–49.
www.thelancet.com/neurology Vol 11 October 2012 905
128 Sammons MA, Antons AK, Bendjennat M, et al. ZNF9 activation of
IRES-mediated translation of the human ODC mRNA is decreased
in myotonic dystrophy type 2. PLoS One 2010; 5: e9301.
129 Onishi H, Kino Y, Morita T, et al. MBNL1 associates with YB-1 in
cytoplasmic stress granules. J Neurosci Res 2008; 86: 1994–2002.
130 Ikezoe K, Nakamori M, Furuya H, et al. Endoplasmic reticulum
stress in myotonic dystrophy type 1 muscle. Acta Neuropathol 2007;
131 Krahe R, Ashizawa T, Abbruzzese C, et al. Eff ect of myotonic
dystrophy trinucleotide repeat expansion on DMPK transcription
and processing. Genomics 1995; 28: 1–14.
132 Davis BM, McCurrach ME, Taneja KL, et al. Expansion of a CUG
trinucleotide repeat in the 3′ untranslated region of myotonic
dystrophy protein kinase transcripts results in nuclear retention of
transcripts. Proc Natl Acad Sci USA 1997; 94: 7388–93.
133 Furling D, Lemieux D, Taneja K, et al. Decreased levels of myotonic
dystrophy protein kinase (DMPK) and delayed diff erentiation in
human myotonic dystrophy myoblasts. Neuromuscul Disord 2001;
134 Botta A, Caldarola S, Vallo L, et al. Eff ect of the [CCTG]n repeat
expansion on ZNF9 expression in myotonic dystrophy type II
(DM2). Biochim Biophys Acta 2006; 1762: 329–34.
135 Margolis JM, Schoser BG, Moseley ML, et al. DM2 intronic
expansions: evidence for CCUG accumulation without fl anking
sequence or eff ects on ZNF9 mRNA processing or protein
expression. Hum Mol Genet 2006; 15: 1808–15.
136 Raheem O, Olufemi SE, Bachinski LL, et al. Mutant (CCTG)n
expansion causes abnormal expression of zinc fi nger protein 9
(ZNF9) in myotonic dystrophy type 2. Am J Pathol 2010;
137 Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic
myopathy: clinical features of a multisystem disorder similar to
myotonic dystrophy. Arch Neurol 1995; 52: 25–31.
138 Vihola A, Bassez G, Meola G, et al. Histopathological diff erences of
myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology
2003; 60: 1854–57.
139 Raheem O, Huovinen S, Suominen T, et al. Novel myosin heavy
chain immunohistochemical double staining developed for the
routine diagnostic separation of I, IIA and IIX fi bers.
Acta Neuropathol 2010; 119: 495–500.
140 Romeo V, Pegoraro E, Ferrati C, et al. Brain involvement in
myotonic dystrophies: neuroimaging and neuropsychological
comparative study in DM1 and DM2. J Neurol 2010; 257: 1246–55.
141 Schoser BG, Ricker K, Schneider-Gold C, et al. Sudden cardiac
death in myotonic dystrophy type 2. Neurology 2004; 63: 2402–04.
142 Harper PS, Van Engelen B, Eymard B, et al. Myotonic dystrophy:
present management, future therapy. Oxford: Oxford University
143 Mathieu J, Allard P, Gobeil G, et al. Anesthetic and surgical
complications in 219 cases of myotonic dystrophy. Neurology 1997;
144 Nishi M, Itoh H, Tsubokawa T, et al. Eff ective doses of vecuronium
in a patient with myotonic dystrophy. Anaesthesia 2004; 59: 1216–18.
145 Kirzinger L, Schmidt A, Kornblum C, et al. Side eff ects of
anesthesia in DM2 as compared to DM1: a comparative
retrospective study. Eur J Neurol 2010; 17: 842–45.
146 Heatwole C, Johnson N, Goldberg B, et al. Laboratory abnormalities
in patients with myotonic dystrophy type 2. Arch Neurol 2011;
147 Gadalla SM, Lund M, Pfeiff er RM, et al. Cancer risk among patients
with myotonic muscular dystrophy. JAMA 2011; 306: 2480–6.
148 Das M, Moxley RT III, Hilbert JE, et al. Correlates of tumor
development in patients with myotonic dystrophy. J Neurol 2012;
published online May 23. DOI:10.1007/s00415-012-6476-8.
149 Mulders SA, van Engelen BG, Wieringa B, et al. Molecular therapy
in myotonic dystrophy: focus on RNA gain-of-function.
Hum Mol Genet 2010; 19: R90–97.
150 Wheeler TM, Sobczak K, Lueck JD, et al. Reversal of RNA
dominance by displacement of protein sequestered on triplet repeat
RNA. Science 2009; 325: 336–39.
151 Mulders SA, van den Broek WJ, Wheeler TM, et al. Triplet-repeat
oligonucleotide-mediated reversal of RNA toxicity in myotonic
dystrophy. Proc Natl Acad Sci USA 2009; 106: 13915–20.
152 Warf MB, Diegel JV, von Hippel PH, et al. The protein factors
MBNL1 and U2AF65 bind alternative RNA structures to regulate
splicing. Proc Natl Acad Sci USA 2009; 106: 9203–08.
153 Wang GS, Kuyumcu-Martinez MN, Sarma S, et al. PKC inhibition
ameliorates the cardiac phenotype in a mouse model of myotonic
dystrophy type 1. J Clin Invest 2009; 119: 3797–806.